An Insight Into Potential of Nanoparticles-Assisted Chemotherapy of Cancer Using Gemcitabine and Its Fatty Acid Prodrug: A Comparative Study
Gemcitabine (dFdC) mediated cancer treatment faces obstacles, due to its high hydrophilicity. A valuable strategy was executed by synthesizing lipophilic fatty acid derivative of dFdC i.e., 4-N-stearoyl gemcitabine (C18dFdC), built-in into polymeric poly-lactic-co-glycolic
acid nanoparticles (PLGA NPs) and compared with that of parent drug. Encapsulation of derivative within NPs was higher (68.24 ± 3.64%) than dFdC and showed comparatively sustained drug release (19.87 ± 1.73% within 12 hours), with a proof of increased biological half life. The
cytotoxicity and flow cytometric analysis displayed enhanced MCF-7 cell inhibition by C18dFdC-NPs with higher uptake compared to dFdC-NPs. Interestingly, like gemcitabine, C18dFdC-NPs did not induce appreciable differences in blood parameters and in vivo tissue
toxicity study demonstrating safe use of derivative at 40 mg/kg dose. In conclusion, the preclinical data obtained in vitro and in vivo demonstrate the C18dFdC-nanocarrier as an advantageous and promising delivery system for cancer treatment along with the potential
to improve the clinical outcome of gemcitabine chemotherapy.
Keywords: CYTOTOXICITY; NUCLEOSIDE ANALOGUE; POLY-LACTIC-CO-GLYCOLIC ACID; STEARIC ACID; STEAROYL-GEMCITABINE
Document Type: Research Article
Publication date: 01 May 2013
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content